. Author manuscript; available in PMC: 2014 Jul 4.

Published in final edited form as: Metallomics. 2014 Feb 11;6(3):437–443. doi: 10.1039/c3mt00364g

Table 1.

IC₅₀values (μM) of [Pt(BDI^QQ)]Cl and cisplatin against various cancerous and healthy cell lines. The errors represent standard deviations.

Cell line	Cancer type	[Pt(BDI^QQ)]Cl	cisplatin
A549	Lung carcinoma	1.2 ± 0.2^a	5.2 ± 1.0^a
HeLa	Cervical adenocarcinoma	2.8 ± 1.7^a	2.3 ± 1.4^a
MCF-7	Breast adenocarcinoma	6.4 ± 1.1	7.4 ± 2.1
HT-29	Colorectal adenocarcinoma	13.6 ± 3.3	15.03 ± 2.1
U2OS	Bone osteosarcoma	3.6 ± 0.1	4.6 ± 0.6
A2780	Ovarian carcinoma	3.2 ± 0.5	0.7 ± 0.2
A2780CP70	Ovarian carcinoma	3.7 ± 0.1	9.6 ±1.6
MRC-5	Lung fibroblast	12.2 ± 2.1	5.3 ± 0.6
A549 (quiescent)	Lung carcinoma	9.5 ± 1.3	14.2 ± 0.2

IC₅₀ values taken from Ref. 27.